Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.

Brian BresslerJennifer JonesTracy S H InTommy LanCristian IconaruJohn K Marshall

Published in: Advances in therapy (2023)

This study estimated long-term persistence in a large population of patients with IBD. At 1 year, over three-fourths of patients remained on UST treatment in all disease cohorts, and over half of patients remained on treatment at 4 years in CD and FCD patients. Biologic-naïve status was significantly associated with higher persistence in patients with CD.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
rheumatoid arthritis
patient reported outcomes
patient reported